A retrospective study of melanoma patients (n=34) who took metformin while receiving either nivolumab or pembrolizumab anti-PD-1 treatment found no change in progression-free survival or overall survival compared to patients receiving anti-PD-1 alone (38). This evidence concerns the gene PDCD1 and melanoma.